--- title: "PTC Therapeutics (PTCT) news: bankruptcy and offering" url: "https://aibio.space/companies/ptc-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PTCT bankruptcy, offering, convertible notes and merger news: PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy. PTC Therapeutics, Inc." --- PTCT PTC Therapeutics, Inc. NASDAQ · United States # PTC Therapeutics (PTCT) news PTCT bankruptcy, offering and convertible notes news Company Updates · 2026-10-29 ## [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Sephience revenue reached $182 million in the quarter, the company acquired ST-920 for $111.0 million upfront, and it now expects total revenue of $1.29 to $1.32 billion for 2026. ## Latest PTC Therapeutics news 1. 2026-09-21 Company Updates [PTC completes acquisition of ST-920 Fabry gene therapy from Sangamo](https://aibio.space/news/ptc-completes-acquisition-st-920-fabry-gene-therapy-sangamo/) PTC says the rolling BLA for ST-920 is expected to be completed in the fourth quarter of 2026, with the goal of accelerated approval. 2. 2026-08-25 Distress [PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy](https://aibio.space/news/ptc-agrees-buy-sangamos-fabry-gene-therapy-st-920-bankruptcy/) PTC Therapeutics will pay $111 million upfront and up to $100 million more in milestones for ST-920, subject to approval by the bankruptcy court. 3. 2026-08-12 Distress [PTC named winning bidder for Sangamo's Fabry gene therapy ST-920](https://aibio.space/news/ptc-named-winning-bidder-sangamos-fabry-gene-therapy-st-920/) PTC says the ST-920 rolling BLA will be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 if the acquisition closes. 4. 2026-07-30 Company Updates [PTC raises 2026 product revenue guidance after second quarter](https://aibio.space/news/ptc-raises-2026-product-revenue-guidance-after-second-quarter/) PTC reported second quarter 2026 total revenue of $361 million, including $239 million of product revenue, and raised full-year product revenue guidance to $850 to $950 million. 5. 2026-06-18 Debt Financing [PTC Therapeutics closes $550,000,000 convertible notes offering](https://aibio.space/news/ptc-therapeutics-closes-550-000-000-convertible-notes-offering/) PTC Therapeutics sold $550,000,000 of 0.0% convertible senior notes due 2031 through Morgan Stanley & Co. LLC as representative of the initial purchasers. The initial conversion price is about $107.48 a share. 6. 2026-06-08 Company Updates [PTC director Alethia Young steps down and stays on as an advisor](https://aibio.space/news/ptc-director-alethia-young-steps-down-stays-advisor/) Alethia Young resigned from the PTC Therapeutics board effective June 8, 2026, and will remain an advisor under a consulting agreement running through June 8, 2027. 7. 2026-05-07 Company Updates [PTC raises 2026 product revenue guidance after first quarter](https://aibio.space/news/ptc-raises-2026-product-revenue-guidance-after-first-quarter/) PTC reported first quarter 2026 total revenue of $273 million and a net loss of $2.8 million, and raised full-year product revenue guidance to $750 to $850 million. 8. 2025-08-07 Mergers [PTC Therapeutics pays about $225.0 million to cancel Censa sepiapterin sales payment rights](https://aibio.space/news/ptc-therapeutics-pays-about-225-0-million-cancel-censa-sales-payments/) Former Censa securityholders holding about 90% of its equity gave up 8% to 12% net sales payments on sepiapterin. PTC will owe milestone payments of about $90.0 million each if sales reach set thresholds. 9. 2025-08-07 Mergers [PTC Therapeutics pays about $225.0 million to cancel Censa sales payments](https://aibio.space/news/ptc-therapeutics-pays-about-225-0-million-cancel-censa-sales-payments/) PTC paid about $225.0 million in cash to former Censa holders who gave up their share of sepiapterin sales, and it is still obligated to make five milestone payments of about $90.0 million each. The filing does not say what the rights were worth. ## PTC Therapeutics at a glance - **Ticker**: PTCT - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $2.13 billion ### Related companies - [Exelixis](https://aibio.space/companies/exelixis/) NASDAQ: EXEL - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN - [Kyntra Bio](https://aibio.space/companies/kyntra-bio/) NASDAQ: KYNB - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX - [Aardvark Therapeutics](https://aibio.space/companies/aardvark-therapeutics/) NASDAQ: AARD - [Innoviva](https://aibio.space/companies/innoviva/) NASDAQ: INVA - [Zeo ScientifiX](https://aibio.space/companies/zeo-scientifix/) OTC: ZEOX - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT ### Also on NASDAQ - [Q/C Technologies](https://aibio.space/companies/q-c-technologies/) QCLS - [Opus Genetics](https://aibio.space/companies/opus-genetics/) IRD - [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) LABT - [biote](https://aibio.space/companies/biote/) BTMD - [Immunic](https://aibio.space/companies/immunic/) IMUX - [20/20 Biolabs](https://aibio.space/companies/20-20-biolabs/) AIDX ## PTC Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$455.2 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | [$534.5 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | | Net income (loss) | [$682.6 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | [-$363.3 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | | Cash from operations | [$711.2 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | [-$107.7 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | | Cash and equivalents | [$984.6 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/) | [$779.7 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | | Short-term investments | [$960.7 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926120223/) | [$360.0 million](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $508.9 million, plus short-term investments of $1.62 billion, $2.13 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about PTC Therapeutics Did PTC Therapeutics file for bankruptcy? Our latest story on this, dated Aug 25, 2026: "PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ptc-agrees-buy-sangamos-fabry-gene-therapy-st-920-bankruptcy/). Has PTC Therapeutics raised money recently? Our latest story on this, dated Jun 18, 2026: "PTC Therapeutics closes $550,000,000 convertible notes offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ptc-therapeutics-closes-550-000-000-convertible-notes-offering/). Has PTC Therapeutics sold convertible notes? Our latest story on this, dated Jun 18, 2026: "PTC Therapeutics closes $550,000,000 convertible notes offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ptc-therapeutics-closes-550-000-000-convertible-notes-offering/). Is PTC Therapeutics involved in a merger or acquisition? Our latest story on this, dated Aug 25, 2026: "PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ptc-agrees-buy-sangamos-fabry-gene-therapy-st-920-bankruptcy/). What is the ticker symbol of PTC Therapeutics? PTC Therapeutics, Inc. trades under the ticker PTCT on NASDAQ. Where is PTC Therapeutics listed? PTC Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:BH3; FWB:BH3; GETTEX:BH3; HAM:BH3; HAN:BH3; MUN:BH3; SWB:BH3; TRADEGATE:BH3; XETR:BH3. What is the SEC CIK of PTC Therapeutics? The SEC Central Index Key (CIK) for PTC Therapeutics, Inc. is 1070081. Its filings are on SEC EDGAR. How many shares does PTC Therapeutics have outstanding? 83,460,802 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-07-30. Which country or territory is PTC Therapeutics listed under? Our directory records PTC Therapeutics, Inc. under United States. What does PTC Therapeutics do? Our directory classifies PTC Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of PTC Therapeutics? The ISIN recorded for PTC Therapeutics, Inc. is US69366J2006. Does aibio.space cover PTC Therapeutics? aibio.space lists PTC Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is PTC Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is PTC Therapeutics profitable? PTC Therapeutics, Inc. reported net income of $682.6 million for the fiscal year ended Dec 31, 2025, and generated $711.2 million of cash from operations, per its annual report to the SEC. How much does PTC Therapeutics spend on research and development? $455.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: PTC Therapeutics Members talk about PTC Therapeutics (PTCT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at PTC Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-13 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/tmb-20260812xex99d1.htm) 2. 2026-06-16 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1070081/000110465926074292/tm2618041d1_ex99-1.htm) 3. 2025-08-07 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01). [Source](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010786/tmb-20250805x8k.htm) 4. 2024-11-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1070081/000107008124000021/tmb-20241107xex99d1.htm) ## Press releases Headlines of PTC Therapeutics's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-29 PR Newswire [PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PTCT on TradingView](https://www.tradingview.com/symbols/NASDAQ-PTCT/). ## SEC filings and registration - **SEC name**: Ptc Therapeutics, Inc. - **CIK**: 1070081 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PTCT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059 - **Phone**: 9082227000 - **Shares outstanding**: 83,460,802 as of 2026-07-29 (10-Q filed 2026-07-30) - **Former names**: PTC THERAPEUTICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/tmb-20260921x8k.htm) filed 2026-09-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/tmb-20260825x8k.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/tmb-20260812x8k.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000017/tmb-20260630x10q.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/tmb-20260728x8k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926075731/tm2618266d1_8k.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926074292/tm2618041d1_8k.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1070081/000110465926071916/tmb-20260608x8k.htm) filed 2026-06-09 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001070081), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details PTC Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PTCT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: PTC Therapeutics, Inc. - **Ticker**: PTCT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US69366J2006 - **Other listed symbols**: DUS:BH3; FWB:BH3; GETTEX:BH3; HAM:BH3; HAN:BH3; MUN:BH3; SWB:BH3; TRADEGATE:BH3; XETR:BH3 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PTCT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ptc-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "PTC Therapeutics (PTCT) news: bankruptcy and offering", 2026-10-31, https://aibio.space/companies/ptc-therapeutics/